ALSFORUMS.COMNewsClinical Trials (USA)

Font Size: LRG / SML

News / America / Clinical Trials

Our appreciation goes out to Medical News Today for having the foresight to provide their news listings by RSS.

To view the full content of the the article you must click the title link and a new window will open to their website.

Latest Clinical Trials / Drug Trials News From Medical News Today.

Top 25 Headlines from the ALS Society of Canada

1. Titan Pharmaceuticals Announces Spheramine® Initial Phase IIb Results
   07/04/2008 - Titan Pharmaceuticals, Inc. (AMEX:TTP) announced initial analyses show that Spheramine® did not meet the Phase IIb clinical study's primary or key secondary endpoints, with no significant differences detected between the Spheramine and sham surgery arms of the study after 12 months of follow-up.
2. Omrix Biopharmaceuticals Initiates Phase II Clinical Trial In Israel For Fibrin Pad Product Candidate
   07/04/2008 - Omrix Biopharmaceuticals, Inc. ("Omrix" or the "Company") (NASDAQ: OMRI) announced that it has enrolled its first patient in a Phase II clinical trial in Israel for its Fibrin Pad product candidate. This is the first clinical trial that will evaluate the Fibrin Pad's performance in surgery where severe bleeding is present and the product is applied directly onto a solid organ. The Phase II clinical trial in Israel is being conducted simultaneously with the Phase II clinical trial in the U.S.
3. M0002 Progresses To Phase IIb Trial Following Positive Results In Cirrhotic Ascites
   07/04/2008 - Movetis NV, a European specialist pharmaceutical company, announced that M0002 is progressing to phase IIb following positive results of a phase IIa multiple-dosing trial for the treatment of ascites, the accumulation of fluid in the abdomen in patients with liver cirrhosis resulting from liver conditions such as hepatitis C, hepatitis B or alcoholism.
4. Advanced Thyroid Cancer Investigational Drug Shows Promise
   07/03/2008 - A study by an international team of researchers found that an experimental drug that stops blood vessels that feed tumors from forming was able, in a small number of patients, to slow down the progression of advanced thyroid cancer that has spread to other sites.
5. SCOLR Pharma, Inc. Advances Extended-Release Ibuprofen With Initiation Of Clinical Study
   07/03/2008 - SCOLR Pharma, Inc. (AMEX: DDD) announced the initiation of the third of three pivotal trials to evaluate the safety and efficacy of its formulation of 12-hour extended-release (ER) ibuprofen for the over-the-counter (OTC) market. The Company expects to complete the trial in late 2008. If approved, the Company believes its ibuprofen product would be the first and only OTC 12-hour, extended-release ibuprofen product on the market in the United States.
6. Aradigm Reports Successful Top-Line Phase 2 Data With Inhaled Liposomal Ciprofloxacin For Cystic Fibrosis
   07/03/2008 - Aradigm Corporation (OTCBB:ARDM) (the "Company") announced positive results from an open-label, two week efficacy and safety study of its once daily inhaled liposomal ciprofloxacin in patients with cystic fibrosis (CF). The study conducted at leading CF centers in Australia and New Zealand enrolled a total of 22 patients.
7. NuPathe Reports Positive Phase I Results For NP101, A Novel Transdermal Patch For Acute Migraine
   07/03/2008 - NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, announced positive Phase I results for NP101, a novel drug-device patch for acute migraine in clinical development.
8. Salix Initiates Phase 3 For Rifaximin In Non-Constipation Irritable Bowel Syndrome
   07/03/2008 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that the Company has initiated patient enrollment in TARGET 1 and TARGET 2, its Phase 3, randomized, double-blind, placebo-controlled, multicenter studies to assess the efficacy and safety of rifaximin 550 mg, dosed three times daily, in the treatment of subjects with non-constipation irritable bowel syndrome (IBS).
9. Peregrine Pharmaceuticals Reports Positive Early Results In Phase II Study Of Bavituximab In Breast Cancer
   07/03/2008 - Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that its lead product candidate bavituximab achieved the pre-specified Stage 1 primary endpoint in its ongoing Phase II clinical trial in patients with metastatic breast cancer. The trial is an open-label, Simon two-stage design to evaluate the safety and efficacy of a combination of bavituximab and docetaxel in metastatic breast cancer patients.
10. Zenith Endovascular Graft Continues To Show Durability
    07/02/2008 - A multicenter trial with up to five years of follow-up continues to support the mid- and long-term durability and safety of the Zenith endovascular graft used for aneurysm repair. "Our study showed that the risk of aneurysm-related death or rupture were exceptionally low, and complications of migration, limb occlusion and device integrity issues were uncommon," said Roy Greenberg, MD, director of endovascular research at The Cleveland Clinic Foundation.
11. Surgeons' Role In Abdominal Aortic Aneurysms Mortality Examined
    07/02/2008 - The impact of surgeons' annual aortic volume and other prognostic indicators have been revealed in early outcomes of ruptured abdominal aortic aneurysm (RAAA) repair in a recent study from the University of Pittsburgh Medical Center. Details of the study have been published in the July issue of the Journal of Vascular Surgery. Fourteen different surgeons performed consecutive open RAAA repairs on 170 patients between January 2001 and June 2007 at the Center.
12. State Of The Art Lecture: What Are The Most Important Ongoing Clinical Trials In Urologic Oncology Worldwide?
    07/02/2008 - ORLANDO, FL (UroToday.com) - Dr. E. David Crawford presented information on challenges facing clinical trials from SWOG, ECOG and CALGB. Patient accrual for clinical trials is only 2-3%. Innumerable layers of rules and regulations have been created with numerous layers that increase costs and delays. He applauded prevention trials such as PCPT, SELECT, Toremifene for PIN and REDUCE. He gave poor marks for randomized treatment trials.
13. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial Of CoFactor(R)
    07/02/2008 - ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based biomodulator of 5-FU (5 fluorouracil), for the treatment of first-line metastatic colorectal cancer. The primary endpoint of the study was progression-free survival, which is expected to mature and be reported by the Company along with safety data later this year.
14. Echo Therapeutics Initiates Clinical Study Of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System In Patients With Diabetes
    07/02/2008 - Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE) announced that it has initiated a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System (tCGM System) in patients with Type 1 and Type 2 diabetes. The Company expects to complete and announce the results of the study in the third quarter of 2008.
15. Schizophrenia And Violence
    07/02/2008 - Some schizophrenia patients become less prone to violence when taking medication, but those with a history of childhood conduct problems continue to pose a higher risk even with treatment, according to a new study by researchers at Duke University Medical Center.
16. Results Of Trial Of Sucrose As Painkiller For Newborns
    07/01/2008 - Using sucrose to reduce pain in newborns undergoing painful procedures should be limited to babies having blood taken (venipuncture) for the newborn screening test but not for intramuscular injections, write Dr. Anna Taddio and co-authors.
17. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating The Use Of Zinc Finger Nucleases To Generate HIV Resistant T Cells
    07/01/2008 - Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the publication of data demonstrating that human immune system cells (CD4 T-cells) can be made resistant to HIV infection by treatment with zinc finger DNA-binding protein nucleases (ZFN(TM)). The data suggest that the ZFN approach, which results in the permanent modification of the CCR5 gene encoding an important receptor for HIV infection, is a promising strategy for the treatment of HIV/AIDS.
18. Sinovac Initiates Phase II Volunteer Enrollment For Split Viron Pandemic Influenza (H5N1) Vaccine
    07/01/2008 - Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, announced the initiation of volunteer enrollment in its Phase II clinical trial for its split pandemic influenza vaccine. The preliminary results from this study are expected to be available in early 2009.
19. Peregrine Pharmaceuticals Doses First Patient In Phase II Trial Of Bavituximab In Patients With Non-Small Cell Lung Cancer
    07/01/2008 - Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC). The primary objective of the study is to assess the overall response rate to the combination of bavituximab with a standard regimen of carboplatin and paclitaxel in NSCLC patients.
20. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment For U.S. Phase II Clinical Trial Of CPP-109 In Patients With Methamphetamine Addiction
    07/01/2008 - Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, announced that it has begun enrollment for its randomized, double-blind, placebo-controlled U.S. Phase II clinical trial evaluating CPP-109 for the treatment of patients addicted to methamphetamine.
21. DG041 Blocks Platelet Aggregation Through A Novel Mechanism And Does Not Increase Bleeding Time When Given Alone Or With Plavix(TM) Or Aspirin
    07/01/2008 - deCODE genetics (Nasdaq: DCGN) announced positive topline results from its latest clinical pharmacology study of DG041, the company's first-in-class antagonist of the EP3 receptor for prostaglandin E2, developed as a next-generation oral anti-platelet therapy for preventing arterial thrombosis without increasing bleeding risk.
22. Emisphere Technologies Announces The Launch Of A Human Clinical Trial For Oral Parathyroid Hormone (PTH)
    07/01/2008 - Emisphere Technologies, Inc. (Nasdaq: EMIS) announced that Novartis Pharma AG has launched a Phase I study in postmenopausal women to determine the safety and tolerability of oral PTH134, a combination of human PTH-1-34 and the absorption enhancer 5-CNAC using Emisphere's proprietary Eligen(R) technology, for the treatment of postmenopausal osteoporosis.
23. Patient Receives VProtect(TM) Luminal Shield In First-Ever Vulnerable Plaque Clinical Trial
    07/01/2008 - An interventional cardiology team led by Professor Patrick W. Serruys successfully placed a vProtect(TM) Luminal Shield in the left anterior descending (LAD) coronary artery of a 64-year-old man at Erasmus Medical Center in Rotterdam.
24. Alkermes Initiates Phase 3 Clinical Study Of VIVITROL(R) For The Treatment Of Opioid Dependence
    07/01/2008 - Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a phase 3 clinical trial of VIVITROL® (naltrexone for extended-release injectable suspension) for the treatment of opioid dependence. The multi-center study is designed to assess the efficacy and safety of VIVITROL in approximately 200 patients diagnosed with opioid dependence. The clinical data from this study will form the basis of a supplemental New Drug Application (sNDA) to the U.S.
25. Greer Completes Enrollment For Pivotal Phase III Trial Evaluating The Efficacy Of Sublingual-Oral Immunotherapy For Treating Short Ragweed Allergies
    06/30/2008 - Greer, a leading developer and provider of allergy immunotherapy products and services, has completed enrollment for its pivotal Phase III clinical trial designed to study the efficacy of sublingual-oral immunotherapy (SLIT) as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen. It is estimated that 30 million Americans are allergic to short ragweed pollen, making it one of the most common allergens.